{"entity":{"id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","aka":["PROSPECTOR"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT07590934 as recruiting, last updated 2026-08-27. Enrolment is 152 planned participants, an estimate. Interventions: AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent). Primary measures include Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs); Part A: Number of participants with dose limiting toxicities (DLTs). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07590934","url":"https://clinicaltrials.gov/study/NCT07590934"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["fpi-2265","ac225-psma","palacaparib","docetaxel"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07590934","phase":"1/2","setting":"A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer","sponsor":"AstraZeneca","participation":[{"nct":"NCT07590934","source":"https://clinicaltrials.gov/study/NCT07590934","fetchedAt":"2026-10-07T16:55:50.238Z","studySha256":"f7747981c437f9d9d715845a17f29f59daa9878472d2c8d88d506f21fef53c6d","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-27","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"99 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":152,"enrolmentType":"ESTIMATED","siteCount":37,"recruitingSiteCount":2,"countries":["Australia","Germany","Italy","South Korea","Spain","United Kingdom","United States"]}],"started":"2026-06-03","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07590934/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"fpi-2265","kind":"drug","name":"FPI-2265","route":"/drugs/fpi-2265/"},{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}